Use of perlecan domain V in treating amyloidogenic disease
US9358273B2 · kind B2 · utility
0Cited by
2References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 6, 2011 |
| Grant date | Jun 7, 2016 |
| Priority date | — |
| Expiry date | Mar 10, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of Aβ peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.